The field spans serious NIH-funded geroscience research and unregulated supplement marketing, often using the same vocabulary. Distinguishing them requires looking at the evidence underneath specific claims, not the field's reputation as a whole.
"Longevity medicine" describes both NIH-funded geroscience and unregulated supplement marketing. The label alone doesn't tell you which one you're looking at.
Geroscience — the study of the biological mechanisms of aging — is a recognized academic discipline, with NIA-funded programs like the Interventions Testing Program rigorously testing candidate compounds across independent labs and genetically heterogeneous mouse cohorts. The same broad "longevity" label is also applied to consumer supplement marketing with far less rigor behind it. The question "is this legitimate" only has a useful answer at the level of a specific claim, not the field as a whole.
The biological framework — the twelve hallmarks of aging, first proposed by López-Otín et al. in 2013 and expanded in 2023 — is broadly accepted within the research community as a structure for understanding why aging happens at a cellular level. Several pharmacological interventions targeting aspects of that framework already have genuine Phase III human outcome trial data: GLP-1 agonists' cardiovascular outcomes and SGLT2 inhibitors' renal and cardiovascular outcomes are not speculative — they're established, FDA-reviewed evidence, even though both drug classes were developed for diabetes, not longevity specifically.
Whether targeting aging itself — rather than a specific disease — extends human healthspan is an open scientific question. No drug has been approved by the FDA for an "aging" indication; the FDA does not currently recognize aging itself as a treatable condition. Compounds with compelling mouse lifespan data, like rapamycin and 17α-estradiol in NIA ITP studies, have not yet been validated in dedicated human longevity outcome trials. The TAME trial, designed to test metformin specifically for this question, illustrates how seriously the research community takes the gap — and how unresolved it still is.
"Is longevity medicine legitimate" is the wrong-shaped question. The better question, for any specific compound or claim, is: what tier of evidence supports it, and does that tier match what's being claimed about it? That's the exact distinction Geroevidence's four-tier system exists to make visible, compound by compound.